ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ngµç×ÓÓÎÏ·Ò½ÉúТ˳£¡·Ç²¡ÀíÐԸ߶ȽüÊÓÑÛÊÓÒ°Ë𺦷ÖÀàÓÐÁËбê×¼

¸å¼þȪԴ£º£ºÖÐɽÑÛ¿ÆÖÐÐÄ ±à¼­£º£ºÖ£Áú·É¡¢¡¢Íõ¶¬Ã· ÔĶÁÁ¿£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±ÌÆÑÞÀö£©¸ß¶È½üÊÓϯ¾íÈ«Çò£¬£¬£¬ÑÏÖØÎ£º£º¦ÑÛ¿µ½¡¡£¡£ÁîÈ˸üΪµ£ÐĵÄÊǸ߶ȽüÊÓÕß±¬·¢Çà¹âÑ۵ĸÅÂʺÜÊǸߣ¬£¬£¬µ«ÁÙ´²ÉÏÕâÒ»ÀàÐÍ»¼ÕßÔçÆÚÕï¶ÏÄÑÌ⣬£¬£¬ÇÒȱ·¦Í³Ò»ÖÎÁÆ·½°¸¡£¡£ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÕÅÐãÀ¼½ÌÊÚÍŶÓDZÐÄÈýÄêÖÂÁ¦ÓÚ¹¥¿ËÕâÒ»ÄÑÌ⣬£¬£¬×îÐÂÑо¿Ð§¹ûÁ¢ÒìÐÔÌá³ö·Ç²¡ÀíÐԸ߶ȽüÊÓÊÓÒ°·ÖÀàбê×¼£¬£¬£¬ÎªÄ¿½ñÈÕÒæÔöÌíµÄ¸ß¶È½üÊӺϲ¢Çà¹âÑÛ»¼ÕßȺÌåÕïÁÆËæ·ÃÌṩÊÓÒ°·ÖÀàµÄ±ê×¼£¬£¬£¬Õ⽫Ϊ¸ß¶È½üÊӺϲ¢Çà¹âÑÛÕâÒ»ÀàÐÍ»¼ÕßµÄÔç·¢Ã÷¡¢¡¢ÔçÕï¶Ï¡¢¡¢ÔçÖÎÁÆÌṩ¼áʵµÄѭ֤ҽѧÒÀ¾Ý¡£¡£

2022Äê3ÔÂ12ÈÕ£¬£¬£¬¹ú¼ÊÑÛ¿ÆÅÅÃûµÚÒ»µÄÆÚ¿¯Ophthalmology½ÒÏþÁËngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÕÅÐãÀ¼½ÌÊÚÍŶӹØÓڷDz¡ÀíÐԸ߶ȽüÊÓÑÛÊÓÒ°Ëðº¦È«Ð·ÖÀà±ê×¼£¨¡°Classification of Visual Field Abnormalities in Highly Myopic Eyes Without Pathological Change¡±£©µÄÔ­´´ÐÔ³¤ÎÄÂÛÖø£¬£¬£¬ÎªÄ¿½ñÈÕÒæÔöÌíµÄ¸ß¶È½üÊӺϲ¢Çà¹âÑÛ»¼ÕßȺÌåÕïÁÆËæ·ÃÌṩÊÓÒ°·ÖÀàµÄ±ê×¼¡£¡£ÕâÊǸÃÍŶÓ×ÔÈ¥Äê8ÔÂÖÁ½ñÔÚOphthalmologyÔÓÖ¾ÉϽÒÏþµÄµÚÈýƪԭ´´³¤ÎÄÂÛÖø¡£¡£

¾Ýͳ¼Æ£¬£¬£¬2000ÄêÈ«ÇòÔ¼ÓÐ1.63ÒÚÈË»¼Óи߶ȽüÊÓ£¨Õ¼×ÜÉú³Ý2.7%£©£¬£¬£¬¶øÔ¤¼Æµ½2050Ä꽫»áÔöÌíµ½9.38ÒÚÈË£¨Õ¼×ÜÉú³Ý9.8%£©¡£¡£ÖµµÃµ£ÐĵÄÊǸ߶ȽüÊÓÕßÍùÍù±¬·¢Çà¹âÑ۵ĸÅÂʺÜÊǸߣ¬£¬£¬»¼²¡·çÏսϿµ½¡ÈËȺºá¿ç½ü6±¶£¬£¬£¬±¬·¢Çà¹âÑÛÐÔÊÓÉñ¾­²¡±ä¸ÅÂʸߴï30%£¬£¬£¬µ«ÁÙ´²ÉÏÕâÒ»ÀàÐÍ»¼ÕßÔçÆÚÕï¶ÏÄÑÌ⣬£¬£¬ÇÒȱ·¦Í³Ò»ÖÎÁÆ·½°¸¡£¡£Îª´Ë£¬£¬£¬ÕÅÐãÀ¼½ÌÊÚÔÚ2019ÄêÂÊÏÈǣͷ×éÖ¯¿ÆÑй¥¹Ø£¬£¬£¬Ï¯¾í7¸ö¹ú¼Ò12Ãû¸ß¶È½üÊÓ¡¢¡¢Çà¹âÑÛ¼°Ê¢Ðв¡Ñ§¶¥¼¶×¨¼Ò£¬£¬£¬ÅäºÏ³ÉÁ¢È«Çò¸ß¶È½üÊӺϲ¢Çà¹âÑÛЭ×÷×飨Glaucoma suspects with high myopia study group£¬£¬£¬¼ò³ÆGSHM£©¡£¡£ÔÚÖÐɽÑÛ¿ÆÖÐÐÄÁÙ´²Ñо¿ÖÐÐÄÆ½Ì¨ºÍ¹ã¶«Ê¡¸ßˮƽҽԺ½¨ÉèÏîĿ֧³ÖÏ£¬£¬£¬Í¬Ê±¿ªÕ¹ÁËÁ½ÏîÇ°ÑØÁÙ´²Ñо¿£¬£¬£¬µÚÒ»Ïî¸ß¶È½üÊӺϲ¢Çà¹âÑÛǰհÐÔÐÐÁÐÑо¿£¨ClinicalTrials.gov×¢²áºÅNCT04302220£¬£¬£¬BMJ Open 2020;10:e039183£»£»£»ÏÖÔÚÒÑÄÉÈë1500ÈË£©£¬£¬£¬µÚ¶þÏî¸ß¶È½üÊӺϲ¢Çà¹âÑÛÁÙ´²Ëæ»ú±ÈÕÕÊÔÑ飨ClinicalTrials.gov×¢²áºÅNCT04296916£¬£¬£¬Trials 2020 Sep 29;211(1)£©¡£¡£½å´ËϵÁÐÑо¿£¬£¬£¬½«Îª¸ß¶È½üÊӺϲ¢Çà¹âÑÛÕâÒ»ÀàÐÍ»¼ÕßµÄÔç·¢Ã÷¡¢¡¢ÔçÕï¶Ï¡¢¡¢ÔçÖÎÁÆÌṩ¼áʵµÄѭ֤ҽѧÒÀ¾Ý¡£¡£ÏÖÔÚ¸ÃϵÁÐÑо¿ÒѽÒÏþÁè¼Ý10ƪÏà¹Ø¸ßˮƽÂÛÖø£¬£¬£¬²¢ÊÚȨ·¢Ã÷רÀû1Ïî¡£¡£

¸ÃÊÂÇéΪGSHMϵÁÐÑо¿µÄÒ»²¿·Ö£¬£¬£¬»ùÓÚ1893·Ý·Ç²¡ÀíÐԸ߶ȽüÊÓÊÓÒ°±¨¸æ£¬£¬£¬Á¬Ïµ¼ÈÍùÊÓÒ°·ÖÀà±ê×¼£¬£¬£¬Í¨¹ýGSHM½¹µã³ÉÔ±¶à¹úÁ¬Ïß¡¢¡¢¶à´ÎÌÖÂÛ×îºó¸æ¿¢¹²Ê¶£¬£¬£¬Á¢ÒìÐÔÌá³ö·Ç²¡ÀíÐԸ߶ȽüÊÓÊÓÒ°·ÖÀàбê×¼¡£¡£¸Ã±ê×¼ÓÉËÄ´óÀà10ÖÖÊÓÒ°ÀàÐÍ×é³É£¨¼ûÏÂͼ1£©£¬£¬£¬°üÀ¨Õý³£ÊÓÒ°¡¢¡¢Çà¹âÑÛÑùÊÓҰȱËð£¨ÅÔÖÐÐݵµã¡¢¡¢±Ç²àõè¾¶¡¢¡¢²¿·Ö¹­ÐÎȱË𡢡¢¹­ÐÎȱË𣩡¢¡¢¸ß¶È½üÊÓÏà¹ØÊÓҰȱËð£¨ÐÄÀíäµãÀ©´ó¡¢¡¢±ÊÖ±õè¾¶¡¢¡¢²¿·Ö±ßÑØÈ±Ë𡢡¢·ÇÌØÒìÐÔȱË𣩼°ÁªºÏȱË𣨱Dzàõè¾¶ÁªºÏÐÄÀíäµãÀ©´ó£©£»£»£»²¢Í¨¹ýº£ÄÚÁ½¼Òµ¥Î»×é¼äºÍ×éÄÚÑéÖ¤Á˸÷ÖÀà±ê×¼ÔÚÏÖʵÖÐʹÓõĿɿ¿ÐÔ£¨¦ÊÖµ ¡Ý0.86£©¡£¡£»£»£»ùÓÚÉÏÊöÊÓÒ°·ÖÀàбê×¼£¬£¬£¬Ê״ᨵÀÔڷDz¡ÀíÐԸ߶ȽüÊÓÈËȺÖÐÒÔÕý³£ÊÓҰΪÖ÷£¨74.1%£©£¬£¬£¬Çà¹âÑÛÑùÊÓҰȱËðºÍ¸ß¶È½üÊÓÏà¹ØÊÓҰȱËð´ÎÖ®£¨»®·Ö10.8%ºÍ15.0%£©£¬£¬£¬¶øÁªºÏȱËð×îÉÙ£¨0.1%£©£¨¼ûÏÂͼ2£©¡£¡£¸ÃÊÓÒ°·ÖÀàбê×¼µÄÌá³öºÍÖÆ¶©£¬£¬£¬ÎªÁÙ´²Ò½Éú¿ìËÙÅбðÕï¶ÏÇà¹âÑÛÑùÊÓҰȱËðÌṩȫй¤¾ß£¬£¬£¬Ò²½«Îª¸ß¶È½üÊӺϲ¢Çà¹âÑÛÑо¿Ìṩ»ù´¡¿ò¼Ü£¬£¬£¬±ãÓÚ²î±ðÁÙ´²ÊÔÑéºÍÊ¢Ðв¡Ñ§Ñо¿Ö®¼äµÄ±ÈÕÕ¡£¡£Ñо¿ÍŶӻ¹·¢Ã÷£¬£¬£¬25.9%·Ç²¡ÀíÐԸ߶ȽüÊÓÕß±£´æÊÓҰȱË𣬣¬£¬µ«ÎÞÏÔ×ÅÖ¢×´µÄ£¬£¬£¬ÊÇδÀ´Ñо¿µÄÖØµãÈËȺ¡£¡£ÍŶӺóÐø½«±¨¸æ²î±ðÊÓÒ°·ÖÐ͵ĺã¾ÃËæ·Ãת±äÇéÐΣ¬£¬£¬ÎªÔçÆÚÖÎÁÆÌṩÒÀ¾Ý¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ1 бê×¼ÊÓÒ°·ÖÀàºÍ¶ÔÓ¦µÄÑ۵ײÊÕÕÌåÏÖ

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ2 ËÄ´óÀà10ÖÖбê×¼ÊÓÒ°ÀàÐÍÂþÑܱÈÀý

ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÁÖ·ï±ò²©Ê¿ºÍ³ÂÊ¿´ï²©Ê¿Îª¸ÃÑо¿ÂÛÎĵÄÅäºÏµÚÒ»×÷Õߣ¬£¬£¬ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄÕÅÐãÀ¼½ÌÊÚ£¨×îºóͨѶ×÷Õߣ©¡¢¡¢ÃÀ¹ú¼ÓÖÝ´óѧʥµØÑǸç·ÖУShileyÑÛ¿ÆÑо¿ËùRobert N. Weinreb½ÌÊں͵¹úº£µÂ±¤´óѧMannheimҽѧԺ¡¢¡¢ÈðÊ¿°ÍÈû¶ûÑÛ¿Æ·Ö×ÓÓëÁÙ´²Ñо¿ËùJost B. Jonas½ÌÊÚΪÅäºÏͨѶ×÷Õß¡£¡£ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄ¡¢¡¢ÑÛ¿ÆÑ§¹ú¼ÒÖØµãʵÑéÊÒ¼°¹ã¶«Ê¡ÑÛ²¿¼²²¡ÁÙ´²Ò½Ñ§Ñо¿ÖÐÐÄΪµÚÒ»µ¥Î»¡£¡£

ÂÛÎÄÁ´½Ó£º£ºhttps://www.aaojournal.org/article/S0161-6420(22)00193-2/fulltext#relatedArticles

¡¾ÍøÕ¾µØÍ¼¡¿